Melatonin, by inhibiting NF-κB activation via the previously-reported MT1 receptor-mediated antiproliferative pathway, can disrupt bi-directional positive interactions between AR-V7 and NF-κB signaling, thereby possibly delaying the development of castration resistance in advanced prostate cancer. The gene discussed is NFKB1; the disease is prostate cancer.